Expansion from an equipment-centered business into the reagent and diagnostic reagent businesses
First written in FY2016. 19 of 43 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-09-28.
0 other companies' latest entry also says "Raised".
- 2026-09-28RaisedManagement Planning
「核酸抽出試薬・消耗品が毎年約10%成⾧」
核酸抽出試薬・消耗品について、毎年約10％成長する見通しが示された。 - FY2026AdvancedAnnual report
「Sales of nucleic acid extraction reagents and related consumables remained firm as cumulative shipments of gene-testing instruments increased, reaching ¥2,037 million for the fiscal year, up 32.5% from the previous fiscal year.」
Revenue from nucleic acid extraction reagents and related consumables reached ¥2,037 million, up 32.5% year on year, as cumulative shipments of PSS Platform instruments increased. - FY2026-H1AdvancedAnnual report
「The Company's gene-testing instruments using its nucleic acid extraction reagents, which it calls the “PSS Platform,” performed steadily, while sales of nucleic acid extraction reagents and related consumables used with those instruments increased as cumulative shipments of the instruments grew. “As cumulative shipments of gene-testing instruments increased, sales of nucleic acid extraction reagents and related consumables remained firm, reaching ¥1,001 million for the six months ended 30 September, up 52.9% year on year.”」
The disclosure cited concrete progress for the “PSS Platform,” which combines instruments with dedicated reagents and consumables, and for the recurring business model, with reagent and consumables revenue reaching ¥1,001 million, up 52.9% year on year, as cumulative shipments increased. - FY2025AdvancedAnnual report
「Sales of nucleic acid extraction reagents and related consumables remained firm, led by increased orders from ELITechGroup, and revenue for the fiscal year was ¥1,545 million, up 8.1% year on year.」
Revenue from nucleic acid extraction reagents and related consumables increased, supported by higher orders from ELITechGroup. - FY2025-H1Declining revenue from reagents and consumables, with recovery expectedAnnual report
「Due partly to the impact of sales recognition shifting from the current quarter to the next quarter as certain OEM customers adjusted their inventories, revenue for the six months ended 30 September was ¥658 million, down 11.4% year on year. Meanwhile, sales of nucleic acid extraction reagents remained firm, led by increased orders from ELITechGroup, and a recovery is expected from the next fiscal period onward.」
Reagents and consumables declined 11.4% year on year due to inventory adjustments by certain OEM customers, while the disclosure cited increased orders for nucleic acid extraction reagents from ELITechGroup and an expected recovery from the next fiscal period onward. - FY2024Continued substantial decline in revenue from reagents and consumablesAnnual report
「For the fiscal year, revenue was ¥1,430 million, down 41.4% year on year.」
Revenue from reagents and consumables was ¥1,430 million, down 41.4% year on year, with the substantial decline continuing. - FY2024-Q3Continued substantial decline in revenue from reagents and consumablesAnnual report
「For the nine months ended 31 December, revenue was ¥1,077 million, down 45.5% year on year.」
Revenue from reagents and consumables was ¥1,077 million, down 45.5% year on year, with the substantial decline continuing. - FY2024-Q2Continued substantial decline in revenue from reagents and consumablesAnnual report
「This segment comprises dedicated plastic consumables, such as reagents and reaction vessels for nucleic acid extraction and PCR testing, consumed in the use of the Company's instruments. For the six months ended 30 September, revenue was ¥743 million, down 48.1% year on year.」
Revenue from reagents and consumables was ¥743 million, down 48.1% year on year, marking another substantial decline following FY2024-Q1. - FY2024-Q1Continued substantial decline in revenue from reagents and consumablesAnnual report
「For the three months ended 30 June, revenue was ¥428 million, down 44.4% year on year.」
Revenue from reagents and consumables was ¥428 million, down 44.4% year on year, continuing to decline from FY2023. - FY2023Continued decline in revenue from reagents and consumablesAnnual report
「For the fiscal year, revenue was ¥2,442 million, down 27.0% year on year.」
Revenue from reagents and consumables was ¥2,442 million, down 27.0% year on year, continuing to decline from the previous fiscal year. - FY2023-Q3Continued decline in revenue from reagents and consumablesAnnual report
「This segment comprises dedicated plastic consumables, such as reagents and reaction vessels for nucleic acid extraction and PCR testing, consumed in the use of the Company's instruments. For the nine months ended 31 December, revenue was ¥1,977 million, down 22.8% year on year.」
Revenue from reagents and consumables was ¥1,977 million, down 22.8% year on year, continuing the decline recorded through the previous quarter. - FY2023-Q2Continued decline in revenue from reagents and consumablesAnnual report
「This segment comprises dedicated plastic consumables, such as reagents and reaction vessels for DNA extraction and PCR testing, consumed in the use of the Company's instruments. For the six months ended 30 September, revenue was ¥1,432 million, down 12.2% year on year.」
Revenue from reagents and consumables was ¥1,432 million, down 12.2% year on year, marking a continued decline. - FY2023-Q1Continued decline in revenue from reagents and consumablesAnnual report
「This segment comprises dedicated plastic consumables, such as reagents and reaction vessels for DNA extraction and PCR testing, consumed in the use of the Company's instruments. For the three months ended 30 June, revenue was ¥770 million, down 21.7% year on year.」
Although sales accompanying the Company's own-brand products were described as strong, segment revenue was ¥770 million, down 21.7% year on year. - FY2022Continued decline in revenue from reagents and consumablesAnnual report
「For the fiscal year, revenue was ¥3,345 million, down 18.4% year on year.」
Revenue from reagents and consumables fell to ¥3,345 million, down 18.4% year on year, reversing the substantial revenue growth recorded in the previous fiscal year. - FY2022-Q3Continued decline in revenue from reagents and consumablesAnnual report
「This segment comprises dedicated plastic consumables, such as reagents and reaction vessels for DNA extraction and PCR testing, consumed in the use of the Company's instruments. For the nine months ended 31 December, revenue was ¥2,563 million, down 6.9% year on year.」
Revenue from reagents and consumables, including DNA extraction and PCR testing reagents and plastic consumables, was ¥2,563 million, down 6.9% year on year. - FY2022-Q2Lower revenue from reagents and consumablesAnnual report
「This segment comprises dedicated plastic consumables, such as reagents and reaction vessels for DNA extraction and PCR testing, consumed in the use of the Company's instruments. For the six months ended 30 September, revenue was ¥1,631 million, down 8.2% year on year.」
Revenue from reagents and consumables, including DNA extraction and PCR testing reagents and plastic consumables, was ¥1,631 million, down 8.2% year on year. - FY2022-Q1AdvancedAnnual report
「For the three months ended 30 June, revenue was ¥983 million, up 28.9% year on year. Revenue increased year on year, particularly in response to global demand for rapid confirmatory COVID-19 testing.」
Revenue from DNA extraction and PCR testing reagents and plastic consumables was ¥983 million, up 28.9% year on year, reflecting efforts to meet demand for rapid confirmatory COVID-19 testing. - FY2021AdvancedAnnual report
「For the fiscal year, revenue was ¥4,100 million, up 162.8% year on year. Revenue increased substantially year on year due particularly to increased production to meet surging global demand for rapid confirmatory COVID-19 testing.」
Revenue from reagents and consumables was ¥4,100 million, up 162.8% year on year, due to increased production to meet demand for rapid confirmatory COVID-19 testing. - FY2021-Q3AdvancedAnnual report
「This segment comprises dedicated plastic consumables, such as reagents and reaction vessels for DNA extraction and PCR testing, consumed in the use of the Company's instruments. For the nine months ended 31 December, revenue was ¥2,752 million, up 187.8% year on year. Revenue increased year on year, particularly in response to global demand for rapid confirmatory COVID-19 testing.」
Revenue from DNA extraction and PCR testing reagents and plastic consumables was ¥2,752 million, up 187.8% year on year, reflecting efforts to meet demand for rapid confirmatory COVID-19 testing. - FY2021-Q2AdvancedAnnual report
「This segment comprises dedicated plastic consumables, such as reagents and reaction vessels for DNA extraction and PCR testing, consumed in the use of the Company's instruments. For the six months ended 30 September, revenue was ¥1,776 million, up 229.7% year on year. Revenue increased year on year, particularly in response to global demand for rapid confirmatory COVID-19 testing.」
Revenue from reagents and consumables was ¥1,776 million, up 229.7% year on year, reflecting efforts to meet demand for rapid confirmatory COVID-19 testing. - FY2021-Q1AdvancedAnnual report
「This segment comprises dedicated plastic consumables, such as reagents and reaction vessels for DNA extraction and PCR testing, consumed in the use of the Company's instruments. For the three months ended 30 June, revenue was ¥762 million, up 187.7% year on year. Revenue increased year on year, particularly in response to global demand for rapid confirmatory COVID-19 testing.」
Revenue from DNA extraction and PCR testing reagents and plastic consumables was ¥762 million, up 187.7% year on year, reflecting efforts to meet demand for rapid confirmatory COVID-19 testing. - FY2020AdvancedAnnual report
「The Company expects sales to expand of dedicated extraction reagents and consumables for its nucleic acid (DNA) extraction automation instruments, the magLEAD series, and fully automated PCR testing instruments, the geneLEAD series, which incorporate the Company's automation technology, in response to global demand for rapid confirmatory COVID-19 testing. Accordingly, reducing mass-production costs through investment in new automated equipment at the Odate Reagent Center and other measures is required and represents an important challenge for business growth. Following its selection on 17 July for the Domestic Investment Promotion for Supply Chain Resilience Subsidy Program, the Company plans to develop production sites and other facilities in Japan and use the subsidy effectively to secure the product supply capacity required in stages.」
The policy of expanding the business beyond instruments into reagents and consumables took concrete form through increased production to meet COVID-19 demand, investment in automated equipment at the Odate Reagent Center, selection for a domestic investment promotion subsidy, and the development of domestic production sites. - FY2020-Q3AdvancedAnnual report
「For the nine months ended 31 December, revenue was ¥956 million, up 19.3% year on year. Revenue increased year on year, particularly in response to global demand for rapid confirmatory COVID-19 testing.」
Revenue from reagents and consumables increased 19.3% year on year to ¥956 million, partly due to efforts to meet demand for rapid confirmatory COVID-19 testing. - FY2020-Q2Lower revenue from reagents and consumablesAnnual report
「This segment comprises dedicated plastic consumables, such as DNA extraction reagents and reaction vessels, consumed in the use of the Company's instruments. In addition to supplying reagents for the Company's own-brand instruments, the Company supplies its DNA extraction reagents to certain OEM customers. Other OEM customers manufacture and sell their own reagents, but have contracts to purchase plastic consumables from the Company. For the six months ended 30 September, revenue was ¥538 million, down 1.3% year on year. Revenue declined year on year.」
The supply model of reagents for the Company's own-brand instruments and certain OEM customers, together with plastic consumables for other OEM customers, continued, but revenue declined 1.3% year on year. - FY2020-Q1Lower revenue from reagents and consumablesAnnual report
「This segment comprises dedicated plastic consumables, such as DNA extraction reagents and reaction vessels, consumed in the use of the Company's instruments. In addition to supplying reagents for the Company's own-brand instruments, the Company supplies its DNA extraction reagents to certain OEM customers. Other OEM customers manufacture and sell their own reagents, but have contracts to purchase plastic consumables from the Company. For the three months ended 30 June, revenue was ¥265 million, down 4.1% year on year. Revenue declined year on year.」
The supply model of reagents for the Company's own-brand instruments and certain OEM customers, together with plastic consumables for other OEM customers, continued, but revenue declined 4.1% year on year. - FY2019Higher revenue, wider operating lossAnnual report
「For the fiscal year, revenue was ¥1,058 million, up 9.8% year on year. Operating expenses were ¥1,091 million, up 12.5%, resulting in an operating loss of ¥32 million, compared with an operating loss of ¥5 million in the previous fiscal year. The Company believes there is no particular cause for concern, as its business relationships with OEM customers have remained stable for many years.」
The supply model for reagents and consumables continued and revenue increased, but the operating loss widened from ¥5 million to ¥32 million due to higher expenses. - FY2019-Q3AdvancedAnnual report
「This segment comprises dedicated plastic consumables, such as DNA extraction reagents and reaction vessels, consumed in the use of the Company's instruments. In addition to supplying reagents for the Company's own-brand instruments, the Company supplies its DNA extraction reagents to certain OEM customers. Other OEM customers manufacture and sell their own reagents, but have contracts to purchase plastic consumables from the Company. For the nine months ended 31 December, revenue was ¥801 million, up 11.6% year on year. Operating expenses were ¥760 million, up 4.8%, and operating profit was ¥40 million, an increase of ¥48 million year on year. Revenue and profit increased year on year.」
As supplies of reagents for the Company's own-brand instruments and certain OEM customers, together with plastic consumables for OEM customers, continued, revenue increased 11.6% year on year, and operating profit improved to ¥40 million from a loss in the same period of the previous year. - FY2019-Q2AdvancedAnnual report
「This segment comprises dedicated plastic consumables, such as DNA extraction reagents and reaction vessels, consumed in the use of the Company's instruments. In addition to supplying reagents for the Company's own-brand instruments, the Company supplies its DNA extraction reagents to certain OEM customers. Other OEM customers manufacture and sell their own reagents, but have contracts to purchase plastic consumables from the Company. For the six months ended 30 September, revenue was ¥546 million, up 20.5% year on year. Operating expenses were ¥499 million, up 11.1%, and operating profit was ¥46 million, an increase of ¥42 million year on year. Revenue and profit increased year on year.」
While the supply model for reagents and consumables continued, revenue increased 20.5% year on year, and operating profit rose from ¥4 million to ¥46 million. - FY2019-Q1AdvancedAnnual report
「For reagents, in addition to supplying the Company's own-brand instruments, the Company supplies its DNA extraction reagents to certain OEM customers. Other OEM customers manufacture and sell their own reagents, but have contracts to purchase plastic consumables from the Company. For the three months ended 30 June, revenue was ¥276 million, up 16.6% year on year. Operating expenses were ¥254 million, up 7.8%, and operating profit was ¥22 million, compared with ¥1 million in the same period of the previous year. Revenue and profit increased year on year.」
Supply of reagents for the Company's own-brand instruments and certain OEM customers, together with supply of plastic consumables to OEM customers, continued. Revenue increased 16.6% year on year, and operating profit rose from ¥1 million to ¥22 million. - FY2018Lower revenue from reagents and consumables and a return to a lossAnnual report
「For the fiscal year, revenue was ¥964 million, down 12.3% year on year. Operating expenses were ¥970 million, down 5.9%, resulting in an operating loss of ¥5 million, compared with operating profit of ¥68 million in the previous fiscal year. Although revenue and profit declined year on year, the Company believes there is no particular cause for concern, as its business relationships with OEM customers have remained stable for many years.」
Reagent and consumables revenue declined, and the business moved from an operating profit in the previous fiscal year to an operating loss. The Company stated that there were no concerns about its long-standing, stable relationships with OEM customers. - FY2018-Q3Lower revenue from reagents and consumables and a return to a lossAnnual report
「For the nine months ended 31 December, revenue was ¥718 million, down 9.1% year on year. Operating expenses were ¥726 million, down 4.9%, resulting in an operating loss of ¥7 million, compared with operating profit of ¥27 million in the same period of the previous year. Revenue fluctuates somewhat from quarter to quarter depending on the operating and inventory conditions of OEM customers. Revenue and profit declined year on year in the nine months ended 31 December because sales of plastic consumables to OEM customers were sluggish. However, the Company believes there is no particular cause for concern, as its business relationships with OEM customers have remained stable for many years.」
Reagent and consumables revenue declined due to sluggish sales of plastic consumables to OEM customers, and the business moved from an operating profit in the same period of the previous year to an operating loss. The Company stated that it had no particular concerns about its long-standing, stable business relationships with OEM customers. - FY2018-Q2Lower revenue and lower profit from reagents and consumablesAnnual report
「For the Company's own-brand instruments and ELITech, the Company supplies DNA extraction reagents and plastic consumables. Other OEM customers manufacture and sell their own reagents, but have contracts to purchase plastic consumables from the Company. For the six months ended 30 September, revenue was ¥453 million, down 13.5% year on year. Operating expenses were ¥449 million, down 9.3%, and operating profit was ¥3 million, down 87.7%.」
The supply model for reagents and consumables continues, but revenue declined due to sluggish sales of plastic consumables to OEM customers, while operating profit fell 87.7% year on year. - FY2018-Q1RestatedAnnual report
「We supply DNA extraction reagents and plastic consumables for our own-brand instruments and for エリテック. Other OEM customers manufacture and sell their own reagents, but have agreements to purchase plastic consumables from us.」
The business model continues to consist of supplying reagents and consumables for the Company's own-brand instruments and to ELITech, as well as plastic consumables to other OEM customers. - FY2017RestatedAnnual report
「We supply our DNA extraction reagents for use with our own-brand instruments and to some OEM customers. Other OEM customers manufacture and sell their own reagents, but have agreements to purchase plastic consumables from us.」
Supply of reagents for our own-brand instruments and to some OEM customers, as well as supply of plastic consumables to OEM customers, continues. - FY2017-Q3AdvancedAnnual report
「① Hitachi High-Tech will sell the nucleic acid extraction system and reagents developed by us. ② Hitachi High-Tech will sell the compact genetic testing system and reagents we develop. ③ Using the technologies of both companies, Hitachi High-Tech will develop and sell a mid-sized genetic testing system. The reagents will be developed by us and third parties and sold by Hitachi High-Tech.」
The strategic capital and business alliance has been defined in specific terms for the reagent business, including Hitachi High-Tech's sale of reagents for nucleic acid extraction and compact systems, and the division of responsibility for developing and selling reagents for mid-sized systems. - FY2017-Q2RestatedAnnual report
「In the reagent business, we supply our DNA extraction reagents for use with our own-brand instruments and for エリテック, and manufacture reagents on a contract basis for some OEM customers. Other OEM customers manufacture and sell their own reagents, but have agreements to purchase plastic consumables from us.」
Operations continue to include reagent supply for our own-brand instruments and for エリテック, contract reagent manufacturing for some OEM customers, and consumables supply to other OEM customers. - FY2017-Q1AdvancedAnnual report
「In the reagent business, we supply our DNA extraction reagents for use with our own-brand instruments and for エリテック, and we also manufacture reagents on a contract basis for some OEM customers.」
The reagent business has progressed beyond a policy statement to specific operations, including the supply of reagents for our own-brand instruments and for エリテック, as well as contract reagent manufacturing for some OEM customers. - FY2016First statedAnnual report
「Building on our previous instrument-centered business, we plan to make a full-scale entry into the reagent business, centered on the DNA extraction reagents used in geneLEAD. Over the medium to long term, we aim to develop and own the genetic diagnostic reagents themselves, rather than limiting our scope to extraction reagents.」
Starting with extraction reagents for geneLEAD, the company aims eventually to own the genetic diagnostic reagents themselves.